Literature DB >> 16964758

Modulation of activator protein-1 (AP-1) and MAPK pathway by flavonoids in human prostate cancer PC3 cells.

Avanthika Gopalakrishnan1, Chang-Jiang Xu, Sujit S Nair, Chi Chen, Vidya Hebbar, Ah-Ng Tony Kong.   

Abstract

In last couple of decades the use of natural compounds like flavonoids as chemopreventive agents has gained much attention. Our current study focuses on identifying chemopreventive flavonoids and their mechanism of action on human prostate cancer cells. Human prostate cancer cells (PC3), stably transfected with activator protein 1 (AP-1) luciferase reporter gene were treated with four main classes of flavonoids namely flavonols, flavones, flavonones, and isoflavones. The maximum AP-1 luciferase induction of about 3 fold over control was observed with 20 microM concentrations of quercetin, chrysin and genistein and 50 microM concentration of kaempferol. At higher concentrations, most of the flavonoids demonstrated inhibition of AP-1 activity. The MTS assay for cell viability at 24 h showed that even at a very high concentration (500 microM), cell death was minimal for most of the flavonoids. To determine the role of MAPK pathway in the induction of AP-1 by flavonoids, Western blot of phospho MAPK proteins was performed. Four out of the eight flavonoids namely kaempferol, apigenin, genistein and naringenin were used for the Western Blot analysis. Induction of phospho-JNK and phospho-ERK activity was observed after two hour incubation of PC3-AP1 cells with flavonoids. However no induction of phospho-p38 activity was observed. Furthermore, pretreating the cells with specific inhibitors of JNK reduced the AP-1 luciferase activity that was induced by genistein while pretreatment with MEK inhibitor reduced the AP-1 luciferase activity induced by kaempferol. The pharmacological inhibitors did not affect the AP-1 luciferase activity induced by apigenin and naringenin. These results suggest the possible involvement of JNK pathway in genistein induced AP-1 activity while the ERK pathway seems to play an important role in kaempferol induced AP-1 activity.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16964758     DOI: 10.1007/bf02968247

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  22 in total

1.  Anti-proliferative and pro-apoptotic effect of carvacrol on human hepatocellular carcinoma cell line HepG-2.

Authors:  Qing-Hua Yin; Feng-Xiang Yan; Xu-Yu Zu; You-Hua Wu; Xiao-Ping Wu; Ming-Chu Liao; Shu-Wen Deng; Lei-Lan Yin; Ying-Zhi Zhuang
Journal:  Cytotechnology       Date:  2011-09-22       Impact factor: 2.058

Review 2.  The Role of Secondary Metabolites on Gynecologic Cancer Therapy: Some Pathways and Mechanisms.

Authors:  Mürşide Ayşe Demirel; İpek Süntar
Journal:  Turk J Pharm Sci       Date:  2017-11-20

3.  Breast cancer resistance protein (BCRP) and sulfotransferases contribute significantly to the disposition of genistein in mouse intestine.

Authors:  Wei Zhu; Haiyan Xu; Stephen W J Wang; Ming Hu
Journal:  AAPS J       Date:  2010-06-26       Impact factor: 4.009

4.  Enhanced Nrf2-dependent induction of glutathione in mouse embryonic fibroblasts by isoselenocyanate analog of sulforaphane.

Authors:  Sans W Emmert; Dhimant Desai; Shantu Amin; John P Richie
Journal:  Bioorg Med Chem Lett       Date:  2010-01-20       Impact factor: 2.823

Review 5.  Flavonoids as therapeutic compounds targeting key proteins involved in Alzheimer's disease.

Authors:  Filipa I Baptista; Ana G Henriques; Artur M S Silva; Jens Wiltfang; Odete A B da Cruz e Silva
Journal:  ACS Chem Neurosci       Date:  2014-01-03       Impact factor: 4.418

6.  Ginkgo biloba extract kaempferol inhibits cell proliferation and induces apoptosis in pancreatic cancer cells.

Authors:  Yuqing Zhang; Aaron Y Chen; Min Li; Changyi Chen; Qizhi Yao
Journal:  J Surg Res       Date:  2008-03-26       Impact factor: 2.192

Review 7.  Hormetic dietary phytochemicals.

Authors:  Tae Gen Son; Simonetta Camandola; Mark P Mattson
Journal:  Neuromolecular Med       Date:  2008-06-10       Impact factor: 3.843

8.  Pharmacokinetic drug interactions between apigenin, rutin and paclitaxel mediated by P-glycoprotein in rats.

Authors:  K Kishore Kumar; Leena Priyanka; K Gnananath; P Ravindra Babu; S Sujatha
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-05-29       Impact factor: 2.441

9.  Apigenin suppresses insulin-like growth factor I receptor signaling in human prostate cancer: an in vitro and in vivo study.

Authors:  Sanjeev Shukla; Sanjay Gupta
Journal:  Mol Carcinog       Date:  2009-03       Impact factor: 4.784

10.  Inhibition of Cell Proliferation and MAP Kinase and Akt Pathways in Oral Squamous cell Carcinoma by Genistein and Biochanin A.

Authors:  Tara L Johnson; Maria B Lai; James C K Lai; Alok Bhushan
Journal:  Evid Based Complement Alternat Med       Date:  2008-02-29       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.